Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA

Oncogene

Volumn 33, Issue 18, 2014, Pages 2395-2404

  Zou, Z ^a   Huang, B ^a,d   Wu, X ^a   Zhang, H ^a,e   Qi, J ^b   Bradner, J ^b   Nair, S ^a   Chen, L F ^a,c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d University of Houston   (United States)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Brd4; Cancer; Degradation; JQ; NF B; Ubiquitination

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; TRANSCRIPTION FACTOR RELA;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SCID MOUSE; UBIQUITINATION;

MUS;

ACETYLATION; AMINO ACID SEQUENCE; ANIMALS; AZEPINES; CELL LINE, TUMOR; HEK293 CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; NF-KAPPA B; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84899927814     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.179     Document Type: Article

References (51)

1. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109: S81-S96.
2. Ghosh S, May MJ, Kopp EB. NF-kB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
3. Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
4. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
5. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
6. Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25: 6817-6830.
7. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8: 33-40.
8. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6: 203-208.
9. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011; 30: 1615-1630.
10. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436.
11. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012; 12: 121-132.
12. Baylin SB, Jones PA. A decade of exploring the cancer epigenome: biological and translational implications. Nat Rev Cancer 2011; 11: 726-734.
13. Sims 3rd RJ, Reinberg D. Is there a code embedded in proteins that is based on post-translational modifications? Nat Rev Mol Cell Biol 2008; 9: 815-820.
14. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006; 25: 6717-6730.
15. Huang B, Yang XD, Lamb A, Chen LF. Post-translational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal 2010; 22: 1282-1290.
16. Chen LF, Greene WC. Shaping the nuclear action of NF-kB. Nat Rev Mol Cell Biol 2004; 5: 392-401.
17. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kB. EMBO J 2002; 21: 6539-6548.
18. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23: 2369-2380.
19. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009; 15: 283-293.
20. Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitorinduced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005; 25: 5429-5444.
21. Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol 2009; 29: 1375-1387.
22. Jeanmougin F, Wurtz JM, Le Douarin B, Chambon P, Losson R. The bromodomain revisited. Trends Biochem Sci 1997; 22: 151-153.
23. Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 2007; 282: 13141-13145.
24. Chiang CM. Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4. F1000 Biol Rep 2009; 1: 98.
25. You J, Croyle JL, Nishimura A, Ozato K, Howley PM. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004; 117: 349-360.
26. Maruyama T, Farina A, Dey A, Cheong J, Bermudez VP, Tamura T et al. A mammalian bromodomain protein, Brd4, interacts with replication factor C and inhibits progression to S phase. Mol Cell Biol 2002; 22: 6509-6520.
27. Jiang YW, Veschambre P, Erdjument-Bromage H, Tempst P, Conaway JW, Conaway RC et al. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc Natl Acad Sci USA 1998; 95: 8538-8543.
28. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012; 7: 247-265.
29. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
30. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al. Selective inhibition of BET bromodomains. Nature 2011; 468: 1067-1073.
31. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
32. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468: 1119-1123.
33. Chung CW. Small molecule bromodomain inhibitors: extending the druggable genome. Prog Med Chem 2012; 51: 1-55.
34. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting Myc dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669-16674.
35. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9: 240-246.
36. Choi KC, Lee YH, Jung MG, Kwon SH, Kim MJ, Jun WJ et al. Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kappaB signaling by preventing RelA acetylation in A549 lung cancer cells. Mol Cancer Res 2009; 7: 2011-2021.
37. Ishinaga H, Jono H, Lim JH, Kweon SM, Xu H, Ha UH et al. TGF-beta induces p65 acetylation to enhance bacteria-induced NF-kappaB activation. EMBO J 2007; 26: 1150-1162.
38. Adcock IM, Tsaprouni L, Bhavsar P, Ito K. Epigenetic regulation of airway inflammation. Curr Opin Immunol 2007; 19: 694-700.
39. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010; 1799: 775-787.
40. Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 2012; 12: 465-477.
41. Oliver SS, Denu JM. Disrupting the reader of histone language. Angew Chem Int Ed Engl 2011; 50: 5801-5803.
42. Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L et al. Down-regulation of NF-kappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem 2012; 287: 28840-28851.
43. Yang XD, Tajkhorshid E, Chen LF. Functional interplay between acetylation and methylation of the RelA subunit of NF-kappaB. Mol Cell Biol 2010; 30: 2170-2180.
44. Yang XD, Huang B, Li M, Lamb A, Kelleher NL, Chen LF. Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. EMBO J 2009; 28: 1055-1066.
45. Zheng G, Schweiger MR, Martinez-Noel G, Zheng L, Smith JA, Harper JW et al. Brd4 regulation of papillomavirus protein E2 stability. J Virol 2009; 83: 8683-8692.
46. Lee AY, Chiang CM. Chromatin adaptor Brd4 modulates E2 transcription activity and protein stability. J Biol Chem 2009; 284: 2778-2786.
47. Jang MK, Kwon D, McBride AA. Papillomavirus E2 proteins and the host BRD4 protein associate with transcriptionally active cellular chromatin. J Virol 2009; 83: 2592-2600.
48. Saccani S, Marazzi I, Beg AA, Natoli G. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med 2004; 200: 107-113.
49. Sen R, Smale ST. Selectivity of the NF-{kappa}B response. Cold Spring Harb Perspect Biol 2010; 2: a000257.
50. Chen LF, Williams SA, Mu Y, Nakano H, Duerr JM, Buckbinder L et al. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 2005; 25: 7966-7975.
51. Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, Shapiro D et al. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 2012; 31: 527-534.